TICKERNERD
Menu
ARTVARTVHealthcare · Biotechnology

ARTV Stock Forecast: Artiva Biotherapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$11
+1.33% on the day

The 6 Wall Street analysts covering Artiva Biotherapeutics, Inc. hold a median 12-month price target of $40 — +249.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 15 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$559.8M
Ticker Nerd rank
38 / 100
Median analyst target
$40
Analysts covering
6
Total return, dividends reinvested
1W
+1.6%
1M
+22.5%
YTD
+166.9%
1Y
+324.1%
From 52W high
−14.5%
From 52W low
+402.2%
$2
$13
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ARTV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Artiva Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
38 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
82
Accruals
58
Size
53
Growth
49
Revisions
47
Quality
42
Issuance
35
Value
31
Volatility
6

Momentum (82): The shares have been drifting up relative to others.

Volatility (6): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ARTV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ARTV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Oct 25Jan 26Apr 26Jul 26ARTVHigh $41Median $40Low $23

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $23Median $40High $41

The green dot is the last close — the median target sits +249.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
8 June 2026NeedhamReiteratesBuy$41
12 May 2026NeedhamMaintainsBuy—
11 May 2026Cantor FitzgeraldMaintainsOverweight—
11 May 2026WedbushMaintainsOutperform—
8 May 2026HC Wainwright & Co.MaintainsBuy—
4 May 2026NeedhamReiteratesBuy—
11 Mar 2026NeedhamReiteratesBuy—
12 Nov 2025HC Wainwright & Co.MaintainsBuy—
17 Oct 2025NeedhamReiteratesBuy—
17 Oct 2025WedbushMaintainsOutperform—
11 June 2025HC Wainwright & Co.AssumesBuy$12
15 May 2025NeedhamMaintainsBuy—
8 Apr 2025NeedhamReiteratesBuy—
26 Mar 2025HC Wainwright & Co.ReiteratesBuy—
25 Mar 2025Cantor FitzgeraldMaintainsOverweight—
25 Mar 2025NeedhamReiteratesBuy—
25 Mar 2025WedbushReiteratesOutperform—
30 Dec 2024HC Wainwright & Co.InitiatesBuy—
13 Nov 2024NeedhamReiteratesBuy—
30 Aug 2024NeedhamReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ARTV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ARTV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Artiva Biotherapeutics, Inc. (ARTV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.3×

Cheaper than 87% of US stocks

Price / sales
—
Price / book
1.6×

Cheaper than 54% of US stocks

EV / EBITDA
−2.4×

Cheaper than 72% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−36.6%

Higher than 25% of US stocks

Return on assets
−22.3%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ARTV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ARTVArtiva Biotherapeutics, Inc.$559.8M
38
SPRYARS Pharmaceuticals, Inc.$558.5M
13
PRMEPrime Medicine, Inc.$560.5M
35
CTNMContineum Therapeutics, Inc.$550.0M
60
ALTAltimmune, Inc.$571.4M
23
ARVNArvinas, Inc.$576.1M
84
VSTMVerastem, Inc.$578.0M
56

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Artiva Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ARTV news & analysis

Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

GlobeNewsWire · 6 Aug 2026positive

Artiva Biotherapeutics reported second quarter 2026 financial results, highlighting translational data presented at EULAR 2026 for AlloNK and an FDA Regenerative Medicine Advanced Therapy designation for AlloNK plus rituximab in refractory rheumatoid arthritis. The company is initiating a Phase 3 registrational trial in approximately 150 refractory RA patients in the second half of 2026, and reported $349.4 million in cash, cash equivalents and investments as of June 30, 2026, expected to fund operations into 2029.

Why it matters — ARTV watchers would care because FDA RMAT designation, the planned Phase 3 trial in refractory RA, and a cash runway into 2029 mark key clinical and regulatory progress for AlloNK.

FAQ

Frequently asked questions about ARTV stock

What is the ARTV stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Artiva Biotherapeutics, Inc. have a median 12-month price target of $40, with estimates ranging from $23 to $41. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ARTV stock a buy right now?

Of the 6 analysts covering Artiva Biotherapeutics, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Artiva Biotherapeutics, Inc. 38 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ARTV?

As at 15 Aug 2026, Artiva Biotherapeutics, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (82 of 100).

Will ARTV stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +249.3% from the last close, and Ticker Nerd's factor model ranks Artiva Biotherapeutics, Inc. 38 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ARTV stock forecast for 2030?

No analyst covering Artiva Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARTV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $23 to $41 over the next 12 months.

How has ARTV stock performed over the past year?

Artiva Biotherapeutics, Inc. returned +324.1% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Artiva Biotherapeutics, Inc. do?

Artiva Biotherapeutics Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients with autoimmune diseases and cancers.

What is the latest news on ARTV?

The most recent item we track (GlobeNewsWire, 6 Aug 2026): "Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights". Artiva Biotherapeutics reported second quarter 2026 financial results, highlighting translational data presented at EULAR 2026 for AlloNK and an FDA Regenerative Medicine Advanced Therapy designation for AlloNK plus rituximab in refractory rheumatoid arthritis. The company is initiating a Phase 3 registrational trial in approximately 150 refractory RA patients in the second half of 2026, and reported $349.4 million in cash, cash equivalents and investments as of June 30, 2026, expected to fund operations into 2029.

Company

About Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients with autoimmune diseases and cancers. Its lead product candidate, AlloNK, is an allogeneic, off-the-shelf, cryopreserved NK cell therapy designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies, driving B-cell depletion. AlloNK is being evaluated in ongoing clinical trials, including company-sponsored and investigator-initiated studies across B-cell driven autoimmune diseases such as refractory rheumatoid arthritis, Sjögren’s disease, systemic lupus erythematosus, lupus nephritis, and others. The company also advances CAR-NK programs, including AB-201 targeting human epidermal growth factor receptor 2 for solid tumors like breast, gastric, esophageal, and bladder cancers, and AB-205 targeting CD5 for hematological malignancies. Artiva Biotherapeutics Inc. operates in the healthcare sector's biotechnology industry, emphasizing accessible cell therapies for serious conditions with significant unmet needs. Incorporated in 2019 and headquartered in San Diego, California, the company leverages NK cell manufacturing technology through strategic partnerships to support its pipeline.

CEO Dr. Fred Aslan M.D. · 115 employees · United States · https://www.artivabio.com